Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com
  • 5.0 (1)
  • Health & Fitness

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. Omega-3 fatty acids after trabeculectomy: Anti-inflammatory ally or bleeding risk?

    16h ago

    Omega-3 fatty acids after trabeculectomy: Anti-inflammatory ally or bleeding risk?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/omega-3-fatty-acids-after-trabeculectomy-anti-inflammatory-ally-or-bleeding-risk Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Omega-3 Fatty Acids after Trabeculectomy: Anti-Inflammatory Ally or Bleeding Risk? Trabeculectomy – a common surgery to lower eye pressure in glaucoma – creates a bleb (a fluid-filled reservoir) under the conjunctiva. After surgery, patients often face ocular surface inflammation and dry eye because of disrupted tear films and inflammation from wound healing. Since omega-3 fatty acids (the anti-inflammatory oils in fish oil) are known to calm inflammation elsewhere in the body, some surgeons and patients wonder: Can fish oil supplements help with eye comfort and bleb health after trabeculectomy, or do they pose a bleeding risk? We review the evidence. Overall, many trials show that the EPA/DHA omega-3 oils can reduce inflammation and improve tear quality after eye surgery, but their direct effects on bleb function are unproven. On the other hand, omega-3s do make platelets less sticky – a theoretical concern for bleeding. Fortunately, large analyses indicate routine omega-3 doses have minimal impact on surgical bleeding. In practice, moderate omega-3 supplements may help with post-op eye comfort, but clinicians should watch for any extra bleeding in high-risk patients. What Are Omega-3 Fatty Acids? Omega-3 fatty acids (especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are healthy polyunsaturated fats found in fatty fish (salmon, mackerel, etc.) or supplements. They cannot be made by our bodies and must come from diet or pills. Omega-3s are famously anti-inflammatory: in the body they compete with the usual inflammatory fats (arachidonic acid) and lead to the production of anti-inflammatory molecules (resolvins and protectins) (). In practical terms, omega-3s can reduce swelling and improve tissue healing in many parts of the body. In the eye, inflammation and tear-film imbalance underlie dry eye symptoms. Omega-3s are thought to improve the oily layer of tears (from the eyelid glands) and calm surface inflammation. Indeed, trials in dry-eye patients have shown that omega-3 supplements can lengthen the time between eye blinks before tearing occurs (tear break-up time) and reduce tear osmolarity (less irritating, more stable tears) () (). These changes translate to patients feeling less dryness, burning and scratchiness when it works. (Note: for severe chronic dry eye, a very large trial (the DREAM study) found 3,000 mg/day of omega-3 did not beat placebo on symptom scores, a result that some experts debate due to study design ().) In summary: Omega-3s are generally anti-inflammatory fats that can improve tear-film stability and may soothe irritated eyes after surgery () (). This forms the rationale for trying them after trabeculectomy. Omega-3 Supplements and Post-Op Eye Comfort Several randomized trials have tested omega-3 supplements for post-surgical dry eye and inflammation. Although no study has looked specifically at trabeculectomy patients, we can apply findings from cataract and refractive surgery cases: Cataract surgery: In a 2017 trial, patients with new dry eye symptoms after cataract removal were given standard treatment with or without omega-3 capsules (each tablet: 180 mg EPA + 120 mg DHA, taken 3 times daily). After a few weeks, the omega-3 group had significantly greater improvement in symptom scores and tear stability than controls (). For example, the average eye-comfort score fell more in the fish-oil group, and tear break-up time improved more on omega-3 (P0.05) (). This suggests that adding fish oil to routine therapy reduced postoperative inflammation and improved ocular surface comfort. Photorefractive keratectomy (PRK): Another small trial looked at patients undergoing PRK (another eye surgery that can cause dry eye). Those who took omega-3 supplements before and after surgery healed quicker and had better vision outcomes and tear stability than those without omega-3 (). (This pilot study supports that omega-3 may speed corneal healing after surgery.) Chronic dry eye (non-surgical): A trial comparing krill oil vs. fish oil vs. placebo in people with dry eye (not after surgery) found both omega-3 groups improved objective tear measures. After 3 months, tear osmolarity and tear break-up time were significantly better with krill or fish oil than placebo (). In that study the krill-oil group (higher EPA ratio) also had a significantly greater drop in symptom scores (patient comfort) than placebo (). Meta-analyses of dry-eye trials generally conclude omega-3s give small but real benefits on tear-film health and symptoms – especially when doses are high and used long-term () (). However, not all reviews are uniformly positive. A 2023 Cochrane review concluded that omega-3s probably have little to no effect on patient-reported dry eye symptoms compared to placebo, though they may improve some tear-test signs (). Importantly, the Cochrane authors noted that combining omega-3 with standard treatments (like artificial tears) seemed more helpful than omega-3 alone. In practice, this suggests fish oil is an add-on therapy: it may work best alongside drops, lid hygiene and other post-op care. What does this mean for trabeculectomy? Trab patients often stop many glaucoma drops (which can irritate the surface) but still experience dry eye and inflammation from surgery trauma. The cataract and PRK trials above imply that omega-3 supplements can make a difference in post-op ocular comfort. While we lack a trial in trab patients, it is reasonable to extrapolate: an omega-3 supplement regimen (e.g. several hundred to a few thousand mg of combined EPA/DHA per day) might reduce irritation, dryness and redness after trabeculectomy, improving patient comfort. Potential Effects on Bleb Health A key question is whether reduced inflammation from omega-3 translates into better bleb healing. The ideal bleb is thin, functioning and leak-free; too much early inflammation can cause scarring and bleb failure. In theory, omega-3’s anti-inflammatory action could help keep fibrosis in check. To date, there are no direct trials of omega-3 on bleb outcomes. However, some clues come from studies of tear biochemistry after trabeculectomy. One 3-year cohort study measured inflammatory lipid mediators in tears before and after trab. It found that pro-inflammatory tear lipids (like certain prostaglandins) dropped markedly after surgery in most patients (). Interestingly, patients who later needed needling of their bleb (a sign of failing bleb with scarring) had higher levels of some inflammatory lipids in their tears than those with healthy blebs (). This suggests chronic inflammation may underlie some bleb problems. By extension, if an intervention like omega-3 could suppress that inflammation, bleb health might benefit. However, this is speculative: no data show that fish oil actually prevents bleb scarring or reduces needling rates. It is also possible that reducing inflammation too much could impair the normal wound closure of the conjunctiva. On balance, most experts would say omega-3’s potential benefits on wound healing via inflammation control are theoretical in the bleb context. We note it as a possible plus, but emphasize the lack of direct evidence. Platelet Function and Bleeding Risk Omega-3s and Platelets: One known effect of EPA/DHA is that they make platelets somewhat less likely to clump. In very high-fish diet populations (like Greenland Inuit), scientists observed prolonged bleeding times and altered platelet fatty acids compared to typical Western diets (). This anti-platelet effect has raised caution among surgeons that omega-3 supplements could increase surgical bleeding. In fact, many guidelines currently advise stopping fish oil before surgery and delaying non-urgent ops for a few days if patients are on fish-oil supplements (). The idea is largely precautionary: fish oil does change cell membranes to be less pro-thrombotic (). However, whether this translates into real harm is the question. Clinical evidence on bleeding risk: Recent analyses have been reassuring. A 2024 meta-analysis of 11 randomized trials (over 120,000 patients) compared bleeding rates in those taking omega-3 supplements vs. controls. It found no significant difference in overall bleeding events (including strokes or gastrointestinal bleeds) between the groups (). Only very high-dose purified EPA (like icosapent ethyl used for heart disease) showed a slight relative increase in bleeding (50% higher risk) – but this change was tiny in absolute terms (0.6% more events) (). Likewise, a large perioperative trial (OPERA, n≈1500) tested giving 8–10 g of fish oil before open-heart surgery and 2 g/day after. The fish-oil group did not have more bleeding – in fact, they had slightly fewer blood transfusions than placebo () (). The odds of major bleeding were not higher (OR≈0.8) in the fish-oil group (). These findings suggest that at least in major surgery, fish oil at high dose didn’t worsen bleeding outcomes. Bottom line on bleeding: In practical terms, normal omega-3 use (roughly 1–3 grams/day of fish oil) appears to have negligible effect on surgical bleeding risk () (). The small impairment in platelet function is mostly offs Support the show

    20 min
  2. Zinc and copper balance: Wound healing without tipping into fibrosis

    17h ago

    Zinc and copper balance: Wound healing without tipping into fibrosis

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/zinc-and-copper-balance-wound-healing-without-tipping-into-fibrosis Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Zinc and Copper Balance: Wound Healing without Tipping into Fibrosis Eye surgery and injuries call for careful healing. One micronutrient under the microscope is zinc – a mineral vital for tissue repair and immunity. Zinc acts as a helper (cofactor) for hundreds of enzymes that rebuild cell membranes, make new cells, and fight infection () (). In fact, the body needs zinc to synthesize DNA and proteins, which lets skin and mucous membranes (like the eye’s surface) renew themselves (). When zinc is too low, wounds heal poorly and skin lesions can appear (). In short, adequate zinc supports epithelial repair (restoring the surface cells of the eye) and boosts immune function to protect against infection () (). However, more zinc is not always better. Because zinc also influences scar tissue processes, patients naturally ask: does extra zinc risk excessive scarring (fibrosis) on the conjunctiva? The good news is that routine zinc supplements do not seem to trigger unwelcome fibrosis. Indeed, zinc is required for enzymes (called MMPs) that help remodel healing tissue. Controlled experiments show zinc actually promotes collagen breakdown and limits excess collagen production in fibroblasts (). For example, one study of hypertrophic (thick) scars found that zinc oxide tape reduced scar redness and thickness by raising collagenase (the enzyme that digests scar collagen) and suppressing new collagen in fibroblasts (). Likewise, laboratory tests on ocular fibroblasts (human Tenon’s capsule cells) showed that zinc oxide inhibited fibroblast growth and lowered key scar factors (like TGF-β and fibronectin). In these eye fibroblast cultures, zinc not only increased cell death of scar-forming cells but also prevented collagen contraction, suggesting an anti-scarring effect (). In summary, the existing science suggests that normal zinc supplementation should help a wound heal normally without “overshooting” into pathological fibrosis. If anything, zinc helps balance the process by activating the enzymes that clear excess matrix and prevent abnormal buildup () (). No strong evidence shows that reasonable zinc doses worsen conjunctival scarring. (Of course, any healing eye can scar from many factors – inflammation, genetics, surgical technique – but zinc itself is unlikely to tip the balance toward too much scar.) Safe Zinc Dosage and Duration For patients, safety is key. The daily need for zinc is quite small (about 8–11 mg for adults) and older guidelines set 40 mg per day as the maximum safe upper limit (). Taking zinc above this long-term is not recommended, because chronic high intake (e.g. 50 mg or more for weeks) can cause problems (). In large amounts, zinc can upset your stomach and even drive down copper and other minerals in the body () (more on that below). Typical supplement range: For wound support, many experts would use a moderate dose, for example 15–30 mg of elemental zinc per day. This is above the RDA but well below the 40 mg upper limit, especially if used short-term. By comparison, specialized wound-care formulas or burn regimens often use doses around 20–25 mg/day to aid repair (), but those are under medical supervision. Duration: We recommend only a short course (e.g. around 2 weeks) of extra zinc after surgery. The body’s demand for zinc is highest early in healing, so a couple of weeks of supplemental zinc can be helpful (). But after that, continuing high doses offers no proven extra benefit and could cause mineral imbalances. Always follow your doctor’s advice on how long to take it. Food vs. supplement: Zinc is found in meats, seafood, dairy, and whole grains, so a healthy diet usually provides the daily amount needed. Supplements are for times (or diets) when zinc might be low. If you take zinc pills, consider taking them with a meal or snack to reduce stomach upset (above). Keep in mind the science: the NIH sets 40 mg/day as the adult safety limit (). Going above that, even with supplements, risks side effects. Short-term (a few weeks) up to ~30 mg/day is generally safe. If your treatment calls for higher doses, do not self-dose – check with your doctor. Copper Co-Supplementation Zinc and copper balance go hand-in-hand. These two minerals compete for absorption. High zinc intakes (especially above ~50 mg daily over time) can block copper absorption, leading to copper deficiency (). Copper is needed for nerves and blood cells, so deficiency can cause anemia and nerve problems if severe (). In practice, taking a low dose of copper along with zinc is a prudent safeguard if you’re taking zinc supplements longer than a couple weeks. Many eye-health formulas (like the AREDS macular degeneration vitamins) contain 2 mg copper along with 80 mg zinc for this reason (). For our shorter 2-week course, the risk is small, but you could include a bit of dietary copper (nuts, seeds, whole grains, shellfish) or a 1–2 mg copper supplement if concerned. This ensures the two minerals stay in balance and supports overall healing. Interactions with Oral Antibiotics If you are on any oral antibiotics, especially tetracyclines or quinolones, timing matters: Tetracyclines (like doxycycline or minocycline): Zinc can bind these antibiotics in the gut and make them less effective. If you must take both, separate the doses. Aim to take the antibiotic at least 2 hours before or 4 hours after taking zinc (). Fluoroquinolones (ciprofloxacin, levofloxacin, etc.): Similarly, take the antibiotic 2–4 hours away from zinc, for the same reason (). Other minerals: Note that calcium, iron, and other minerals (from food or supplements) can also block zinc uptake. To avoid competition, some recommend taking zinc either on an emptier stomach or at least 2 hours apart from high-calcium meals or iron pills (). In short: if you’re using an antibiotic like doxycycline or ciprofloxacin, plan your schedule. For example, if you take doxycycline with breakfast, consider taking zinc in the afternoon or vice versa. Keeping a few hours apart ensures that both the antibiotic and zinc are properly absorbed. Gastrointestinal (GI) Side Effects Zinc supplements can irritate the stomach, especially on an empty stomach. Common symptoms can include nausea, abdominal pain, vomiting or diarrhea (). This is more likely with high doses or lozenge lozenges kept in the mouth for too long. To minimize these effects: Take zinc with a meal or snack (unless your doctor says otherwise). Even though taking it with food slightly reduces absorption, a modest meal is fine to protect your stomach. Drink a full glass of water with the tablet. If it still upsets you, try a smaller dose or a different salt form (e.g. zinc gluconate or acetate are common), again always under doctor advice. Reportedly, doses above 50 mg are most often where nausea/vomiting appear (). By staying modest (~15–30 mg) and short-term, most people tolerate zinc well. If severe GI upset occurs, stop and consult your doctor. Patient-Friendly Guidelines: 2 Weeks Post-Op For practical post-surgery care, here’s a cautious zinc plan at the two-week mark: Check with your doctor first. Zinc is generally safe at recommended doses, but individual conditions vary. Always let your surgeon or doctor know you plan to take supplements. Use a moderate dose. If approved, take around 15–25 mg of elemental zinc per day. (Many over-the-counter supplements specify the mg content of elemental zinc.) This is above a normal diet but below safety limits. Limit duration. Plan to take zinc for about 2 weeks only, starting roughly in the second week after surgery when you have stabilized eating habits. This timing matches when cell division ramps up in healing. Take with food. Especially if you notice stomach upset. A meal will decrease GI side effects and will not significantly impact the benefit at this dose. Separate from antibiotics. If you are taking any tetracycline or fluoroquinolone pills elsewhere in your regimen, schedule them at least 2–4 hours apart from the zinc dose (). For instance, one could be morning, the other late afternoon. Maintain normal diet. Continue a balanced diet rich in protein (for building blocks) and vitamin C (for collagen formation) alongside zinc. Include copper-rich foods like nuts and shellfish if possible. Watch for side effects. If nausea, vomiting, or diarrhea start, reduce the dose or discuss alternatives (maybe switching form or pausing zinc). If you develop any neurological symptoms (very rare) or signs of copper deficiency, contact your doctor. Stop after two weeks. The idea is to use zinc as a short “boost” for early healing. After two weeks, evidence of additional benefit is lacking, so it’s safest to discontinue. At that point, natural diet should be sufficient to support continued healing. Conclusion: Zinc is a key player in healing and immune defense, and giving a short course of moderate zinc can help ensure proper repair of the ocular surface. Used responsibly, it should not cause excessive conjunctival scarring – in fact it may even help normalize the repair process () (). By sticking to recommended doses, limiting duration, pairing with copper if needed, and minding drug interactions, patients can benefit from zinc’s suppo Support the show

    10 min
  3. N-acetylcysteine (NAC): Antioxidant replenishment and antifibrotic potential

    18h ago

    N-acetylcysteine (NAC): Antioxidant replenishment and antifibrotic potential

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/n-acetylcysteine-nac-antioxidant-replenishment-and-antifibrotic-potential Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction N-acetylcysteine (NAC) is a supplement of the amino acid cysteine that has long been used as a mucolytic (to thin mucus) and as an antidote for acetaminophen overdose. More recently, doctors and researchers have studied NAC for its role in boosting antioxidants and controlling scarring. NAC enters cells and is converted to cysteine, which is the building block for glutathione, a major natural antioxidant in the body () (). By helping the body make more glutathione, NAC can help neutralize harmful free radicals. In the eye, this antioxidant action may protect delicate tissues. NAC has been shown to reduce oxidative damage in animal models of glaucoma () and to improve retinal cell function in patients with inherited retinal disease (). At the same time, NAC appears to interfere with fibrosis (the scarring process driven by TGF-β) in laboratory studies, suggesting it might soften the wound-healing response that can cause bleb failure after glaucoma surgery () (). This article reviews what we know about NAC’s antioxidant and antifibrotic effects, how it may affect the eye and body, its usual dosing and side effects, and whether it is safe to start after glaucoma surgery. We also suggest how future studies could test NAC’s impact on bleb healing and survival. NAC and Glutathione Synthesis Glutathione (GSH) is a small molecule that cells use to quench free radicals and repair oxidative damage. Our bodies must continually make glutathione, and that requires the amino acid cysteine. NAC is a modified form of cysteine that can enter cells easily. Once inside, NAC is converted to cysteine and boosts glutathione production () (). For example, a review article notes that “NAC’s antioxidant effect is due to [its] ability to act as a reduced glutathione (GSH) precursor” (). In other words, NAC provides the raw material for more glutathione, which in turn helps neutralize harmful oxidants. (Indeed, this is the same principle behind giving NAC for acetaminophen poisoning — it spares glutathione so the liver toxin can be cleared.) In practical terms, taking NAC supplements can raise cellular cysteine and glutathione levels. One study in a mouse model of normal-pressure glaucoma found that NAC increased glutathione in retinal cells and suppressed oxidative stress (). Antioxidant Effects of NAC Because glutathione is so central to our cell’s defense against damage, boosting it can have wide-ranging effects. NAC itself can also act as a direct antioxidant. One mechanism is that NAC (or glutathione made from it) can scavenge harmful molecules like hydrogen peroxide or reactive aldehydes. Another is that NAC helps break unwanted chemical bonds (disulfides) in damaged proteins or mucus, which can restore normal function (). A short review explains that together these actions give NAC broad chemoprotective power: it neutralizes toxic electrophiles, restores glutathione, and even breaks down problematic protein cross-links (). In more biological terms, NAC relaxes mucus in the lungs, protects the liver, and reduces oxidative stress in many tissues. In the eye, oxidative stress is a key factor in many diseases including glaucoma and retinal degeneration. Recent laboratory studies found that NAC can dial down eye-specific oxidation. In a rat glaucoma model with high eye pressure, daily NAC injections plus a glaucoma drop (brimonidine) reduced retinal oxidative damage compared to controls (). In genetic models of glaucoma where pressure is normal, NAC preserved retinal ganglion cells by blocking stress signals (via HIF-1α and autophagy pathways) (). In patients, a small clinical trial gave oral NAC to men with retinitis pigmentosa and found improvements in cone cell function (likely due to reduced oxidative stress) (). These findings suggest NAC can act as an eye-protective antioxidant both systemically and locally. NAC and the TGF-β Fibrotic Pathway After any surgery, including glaucoma (filtering) surgery, the body’s natural healing response involves fibroblast cells laying down scar tissue. In filtering surgery, excessive fibrosis can close the new drain (bleb) and cause the surgery to fail. A key driver of fibrosis is transforming growth factor beta (TGF-β), a signaling protein that tells cells to become scar-forming myofibroblasts. Studies in eye cells show that NAC can blunt this pathway. For example, one laboratory study treated human retinal pigment epithelial cells with TGF-β1, which normally causes them to turn into migratory myofibroblasts (involved in scarring). Adding NAC to these cells kept them from changing. In fact, NAC inhibited TGF-β1-driven transdifferentiation: it prevented the rise in smooth muscle actin, fibronectin, and collagen that TGF-β1 normally causes (). The research suggested that NAC’s antioxidant action lowered reactive oxygen species and blocked MAP kinase signaling triggered by TGF-β1, thus stopping the fibrotic switch (). (In plain terms, NAC prevented cells from becoming scar-making myofibroblasts.) Similarly, other studies have found that NAC can suppress TGF-β–induced fibrosis in lung and other tissues. One 2009 study in human lung fibroblasts showed NAC reverses TGF-β1–driven fibrosis markers: it stopped gel contraction, and blocked production of fibronectin and α-smooth muscle actin (). By extension, NAC might also blunt TGF-β–driven scarring in the eye. Though direct clinical data in glaucoma surgery are lacking, the lab evidence supports the idea that NAC can modulate the TGF-β fibrotic pathway, potentially reducing scar formation. Moreover, NAC influences enzymes involved in tissue remodeling. For instance, corneal cell studies indicate that NAC reduces MMP-9 (matrix metalloproteinase-9) secretion and slows cell migration (). MMP-9 breaks down extracellular matrix and is linked to inflammation; dampening MMP-9 may help stabilize healing tissues. In summary, NAC seems to exert an antifibrotic influence by both damping the TGF-β signals and lowering enzymes that drive scar remodeling () (). Ocular and Systemic Evidence on NAC Ocular Data Beyond its antifibrotic and antioxidant effects seen in cell studies, NAC has been tested in several eye-related conditions. In dry eye, NAC eye drops have been used (anecdotally and in small trials) to improve tear quality by breaking up mucus, thanks to its disulfide-reducing action (). For glaucoma, most of the evidence is preclinical: animal and lab models suggest NAC could protect retinal cells and limit scarring. As noted above, glaucoma models showed less retinal stress and ganglion-cell loss with NAC treatment (). A landmark phase I trial in retinitis pigmentosa showed that high-dose oral NAC improved cone photoreceptor function in patients (), demonstrating that NAC can reach and help eye cells in humans. These studies indicate NAC can reach ocular tissues (for example, measurable NAC levels were found in eye fluid) and exert its effects. Systemic Data and Dosing Systemically, NAC is sold as a dietary supplement and used as a prescription drug. Typical oral dosing is 600–1200 mg per day, often divided into two or three doses. In clinical trials, doses up to 1800 mg three times daily have been tested (), but the usual recommended range for antioxidant purposes is 600–1200 mg daily. NAC is well absorbed orally, though its bioavailability is modest. Because it supplies cysteine, high-dose NAC supplementation can raise glutathione levels gradually over days to weeks. NAC is generally well tolerated. Common side effects are gastrointestinal. According to drug references, NAC can cause nausea, vomiting, diarrhea or constipation in some people (). Occasionally it causes headache, dizziness or rash, but serious allergic reactions to oral NAC are rare. In the JCI retinitis pigmentosa trial, adverse effects were mostly mild GI upset; some patients needed dose reduction, but none had severe issues (). In summary, at doses around 600–1200 mg/day, NAC’s side effects are usually mild and transient (). NAC After Glaucoma Surgery (Trabeculectomy) Trabeculectomy is a surgery to lower eye pressure by creating a drainage bleb. The big risk after surgery is scarring that closes the bleb. Ophthalmologists already use anti-scarring agents like mitomycin C at surgery to improve success rates. NAC’s profile suggests it could be useful as a safer anti-scarring agent if given after surgery. Starting NAC two weeks after surgery seems reasonable because initial wound closure is complete by then, but scar remodeling is still active. By two weeks, the conjunctival wound has closed, and systemic NAC might gently restrain the fibroblasts before they lay down thick scar tissue. There are no clinical trials yet on NAC for post-trabeculectomy care, but the available evidence (antioxidant and antifibrotic) suggests a potential benefit with low risk. Safety considerations: NAC does not usually impair normal wound healing or carry serious surgical risks. However, caution is advised with certain cardiovascular drugs. In particular, NAC can interact with nitroglycerin (and related nitrate medications). NAC can potentiate the blood pressure lowering effect of nitrates – in Support the show

    14 min
  4. Aqueous Humor and Tear Biomarkers: July 2026 Omics Updates

    2d ago

    Aqueous Humor and Tear Biomarkers: July 2026 Omics Updates

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/aqueous-humor-and-tear-biomarkers-july-2026-omics-updates Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Glaucoma, a leading cause of irreversible vision loss, can be hard to detect early. Researchers are now looking at biomarkers in the eye’s body fluids – the aqueous humor (the fluid inside the front of the eye) and tear fluid (the film covering the eye) – to find signs of disease. New “omics” technologies (advanced protein and metabolite profiling) allow scientists to take a detailed molecular snapshot of these fluids. Recent studies (June–July 2026) have identified candidate markers in tears and aqueous humor that might help in diagnosing glaucoma or predicting its progression () (). In this update, we summarize the latest findings on tears and aqueous humor, describe how these studies were done, and discuss what it will take to turn these discoveries into real clinical tests. Tear Fluid Biomarkers Tear fluid is easy to collect (for example, by capillary tubes or filter paper), making it an attractive source of markers. Modern proteomic methods (mass spectrometry) can detect dozens of proteins in a tiny tear sample. A recent tear proteomics study of normal-tension glaucoma (a form of glaucoma with normal eye pressure) found 15 proteins that differed in patients whose visual fields were worsening (). For example, they identified the antioxidant protein peroxiredoxin-4 (PRDX4) and other proteins linked to oxidative stress. One protein, GNAI1, gave a high diagnostic score (AUC≈0.89) in distinguishing rapid progressors from slow progressors (). This suggests tear proteins may predict disease progression (prognostic use) rather than just presence of disease. Another study (in Eye Discovery, June 2026) looked across several glaucoma types and tear compositions, finding unique patterns for each subtype. These preliminary results hint that tear markers might eventually help subtype glaucoma or monitor changes, but they need confirmation. Sampling methods matter. Tears can be collected by Schirmer strips or capillary tubes, and these methods give slightly different results – for example, capillary collection is less irritating and preserves more tear proteins (). Such technical details can affect reproducibility, so it’s important to standardize collection when comparing studies. Overall, tear studies show promise. They have identified candidate biomarkers (linked to oxidative stress and inflammation) () (). But most findings are so far from small groups of patients. Larger validation studies are needed before any tear test could be used in the clinic (). Aqueous Humor Biomarkers The aqueous humor is the clear fluid bathing the front of the eye. It is obtained during procedures like cataract or glaucoma surgery. Because volumes are small, each sample is precious. Recent studies have profiled its content to find glaucoma clues: Protein and EV profiling: One work used label-free proteomics to map the protein “portraits” of aqueous humor in two common glaucoma types (primary open-angle and pseudoexfoliation glaucoma) (). They found many proteins that differed by disease type. (This study is under peer review but highlights how mass spectrometry can reveal glaucoma-specific protein changes.) Exosomal miRNA: Tiny vesicles called extracellular vesicles (exosomes) carry microRNAs (miRNAs) that regulate genes. A recent pilot study sequenced miRNAs from aqueous humor–derived exosomes in two glaucoma forms. It found, for example, that miR-451a was higher in primary open-angle glaucoma and miR-26a-5p higher in exfoliation glaucoma, while the anti-scarring miR-29a-3p was down in both types (). These miRNAs target extracellular-matrix and fibrotic pathways. As the authors note, this “first profile” of AH exosomal miRNAs highlights potential biomarkers (and even therapeutic targets) for glaucoma (). In lab tests, boosting miR-29a-3p reduced fibrotic changes in eye cells, hinting at a disease link (). Spectral fingerprinting of exosomes: A novel diagnostic approach used surface-enhanced Raman spectroscopy on antibodies that captured AH exosomes. An AI model then classified spectra from glaucoma vs control samples. Impressively, this method achieved ~91% accuracy (AUC=0.96) in distinguishing glaucoma patients (). It shows that even without identifying individual molecules, complex spectral patterns from AH exosomes can serve as diagnostic signatures. Metabolites and lipids: Metabolomic studies (measuring small molecules) have yielded clues too. A recent lipidomic analysis found that glaucoma patients had significantly higher levels of lipoxin A4 (an anti-inflammatory lipid) and its precursor arachidonic acid in their aqueous humor (). This was traced to glaucoma medications: for example, the common drug latanoprost was shown to induce lipoxin production in eye tissues () (). These findings suggest that conventional treatment alters lipid pathways, which now emerge as glaucoma “signatures.” In sum, AH studies are uncovering both molecular markers (specific proteins, miRNAs, lipids) and patterns that differ in glaucoma. Many of the identified changes point to disease pathways (see below). Diagnostic vs. Prognostic Utility and Reproducibility A key question is whether a marker indicates glaucoma is present now (diagnostic) or predicts what happens next (prognostic). In tears, the NTG study was aimed at progression (prognosis) (). In contrast, the AH exosome Raman study was purely diagnostic (glaucoma vs healthy) (). The exosomal miRNA pilot also focused on subtype diagnosis (). Most discovery studies to date are diagnostic in nature. However, none of these putative biomarkers is ready for clinical use. As one review notes, despite identifying many candidates tied to oxidative stress, inflammation or vascular dysfunction, no molecular biomarker has yet been validated for routine glaucoma diagnosis () (). Reproducibility remains a challenge: different labs use different tear collection methods, protein assays, and analytical platforms (). Even aqueous humor studies are small and usually single-center. Validation cohorts (independent patient groups) are rare. For example, the tear proteomics report did not test its biomarkers in a separate population; it only used statistical analysis on the study group (). Thus, while these findings are encouraging, they should be viewed as early leads. Larger-scale studies are required to confirm whether the same markers emerge in other patients and to rule out false positives. In practice, a combination of several markers (a signature panel) might be needed to reach high accuracy. Rigorous standardization of sample handling and analysis will be essential to make results reproducible across clinics. Pathway Enrichment and Biological Insights Beyond individual molecules, researchers look for common pathways that glaucoma targets. Many of the differing molecules fall into a few themes: oxidative stress, inflammation, and extracellular matrix (ECM) remodeling (). For instance, PRDX4 in tears is an antioxidant enzyme, and the AH miRNA results involved ECM-related miRNAs (). Metabolomic analyses reinforce these ideas. A recent meta-analysis pooling data from multiple studies found that pathways involving arginine and proline metabolism were consistently altered in glaucoma – in both aqueous humor and blood (). Arginine/proline metabolism is linked to oxidative stress and neurodegeneration, suggesting these processes play a central role (). The lipoxin study highlighted the arachidonic acid–lipoxin pathway. Lipoxin A4 is a natural anti-inflammatory mediator. Its elevation in glaucoma patients’ AH (likely driven by eye-drop medications) suggests a drug-induced anti-inflammatory response () (). This ties into broader evidence that resolving inflammation may be neuroprotective in glaucoma. In summary, pathway analyses of the new biomarkers point to known glaucoma mechanisms (oxidative damage, immune signaling, wound healing in the eye) () (). These insights help explain why certain markers change and can guide future targets for therapy or monitoring. Steps Toward Clinical Translation Turning these omics findings into a useful clinical test will require many steps. First, candidate markers must be confirmed in larger, independent cohorts. Studies should include diverse populations and controls (e.g. cataract patients) to ensure specificity to glaucoma. Multicenter trials would help establish consistency. Second, a practical assay must be developed. This likely means moving from broad discovery (mass spec, sequencing) to targeted tests. For example, a few key proteins or miRNAs could be measured by antibody-based tests or PCR assays. Any exosome-based test needs a simple way to isolate them (commercial kits) and robust readout (like a Raman sensor or PCR panel). These assays must be optimized for speed, cost, and reproducibility. Regulatory validation will involve defining clear cut-off values, testing sensitivity/specificity in the real world, and comparing with standard glaucoma exams. In the case of tears, methods to collect and store the fluid must be standardized across clinics (). The powerful AI-based exosome classifier () illustrates what is technically possible, but to become a routine test it would need to be replicated (e.g. with blinded new samples) and automated into a user-fri Support the show

    12 min
  5. Laser Therapies Beyond SLT: July 2026 Protocol Innovations

    3d ago

    Laser Therapies Beyond SLT: July 2026 Protocol Innovations

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/laser-therapies-beyond-slt-july-2026-protocol-innovations Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Laser Therapies Beyond SLT: July 2026 Protocol Innovations Selective Laser Trabeculoplasty (SLT) is a well-known laser treatment that lowers eye pressure by targeting the eye’s drainage tissue (trabecular meshwork). Recent studies (July 2026) have explored new laser approaches and tweaks to SLT for glaucoma and ocular hypertension. These include modified SLT methods (like non-contact SLT and pulsed lasers), micropulse laser techniques, and canal-focused procedures (using either lasers or tiny implants). We summarize the latest dosing (energy), retreatment rates, pressure‐drop results, and safety findings, and explain what they mean for patients. Modified SLT Approaches (Direct SLT and Micropulse SLT) Researchers continue to refine SLT itself. For example, a new “direct SLT” system treats the drainage tissue without touching the eye. In a large series of 218 eyes, Goldberg et al. (2026) found that 67.0% of eyes reached their target pressure at 2 months after direct SLT【Goldberg2026】. The average eye pressure fell about 3.4 mmHg (a 15.6% drop) from a baseline of ~19.7 mmHg【Goldberg2026】. Importantly, eyes that had never used pressure drops before did even better: about 78.4% of these “treatment-naïve” eyes hit the pressure goal, versus 63.5% of eyes already on medication【Goldberg2026】. Side effects were mild: over half of eyes had a small subconjunctival bleed (a tiny bruise on the eye surface), and only 1.8% had a brief pressure spike; no serious complications were seen【Goldberg2026】. Another line of work uses a pulsed laser for the same 360° treatment area of SLT. This “micropulse” SLT applies many tiny bursts of laser energy to gently stimulate the drainage meshwork. In a head-to-head trial, Abramowitz et al. (2018) found that one year after treatment, micropulse SLT and standard SLT gave very similar pressure drops. About 30–37% of eyes in each group had a ≥3 mmHg drop or ≥20% reduction in pressure【Abramowitz2018】. The big difference was comfort: patients reported significantly less pain during and after the micropulse laser (P=0.005)【Abramowitz2018】. In short, modified SLT methods – whether non-contact or pulsed – appear as effective as standard SLT in lowering pressure, with the advantage of easier delivery and less discomfort【Goldberg2026】【Abramowitz2018】. New Micropulse Laser Treatments Beyond SLT-style procedures, micropulse lasers have been applied in other ways. One major application is ciliary-body cyclophotocoagulation, where laser energy is delivered through the sclera (the white of the eye) to reduce fluid production. In a recent retrospective study of 118 eyes with various refractory glaucomas, Toptan et al. (2026) reported dramatic pressure reductions from micropulse transscleral laser. After one treatment session, mean intraocular pressure (IOP) fell by about 46–56% across glaucoma types (for example, 46.5% in primary open-angle glaucoma, 50.4% in neovascular glaucoma, up to 56.2% in juvenile glaucoma)【Toptan2026】. Overall, the group-wide drop was 48.8%. Initially 66.9% of eyes succeeded (reached target IOP) after one session, and after allowing repeat treatments about 75.4% met the goal by 12 months【Toptan2026】. In practice, most patients (67%) needed just one session, while 28% required two and 5% three sessions up to one year【Toptan2026】. Notably, this powerful pressure lowering came with very few serious side effects. No eye developed dangerous chronic low pressure (hypotony) or shrunken eye (phthisis), complications seen with older cyclodestructive lasers【Toptan2026】. A few mild issues were reported (temporary eye inflammation in 3 patients, small bleeding in 1), and one patient had a transient pupil dilation【Toptan2026】. In summary, micropulse transscleral therapy can cut IOP roughly in half with a 1–2 session protocol, at the cost of mostly minor and temporary effects. The dosing used in these studies was high-power but pulsed: typically a 2,000 mW (2 W) laser with a 31% duty cycle (short “on” bursts totaling about 160 seconds of delivery around the eye)【Toptan2026】. This delivered about 70–80 joules of energy per session. The key is that micropulsing lets the tissue cool between bursts, minimizing collateral damage. Canal-Based Procedures (Excimer Trabeculostomy and Canaloplasty) Researchers are also targeting the eye’s fluid canal (Schlemm’s canal) with new techniques. Excimer Laser Trabeculostomy (ELT) is one such method: a tiny ultraviolet laser makes microscopic holes through the trabecular meshwork into Schlemm’s canal. In a small pilot study (Kallab et al., 2026), patients undergoing cataract surgery plus ELT showed measurable improvement in aqueous outflow. Dye angiography before and after the procedure found a significant increase in fluid flow (p=0.03) across the treated drainage area【Kallab2026】. This suggests ELT can enhance the natural channels, although large-scale pressure data are still pending. Separately, non-laser canal procedures (sometimes grouped here) are showing large pressure drops. For instance, an OMNI canaloplasty/trabeculotomy – a micro-catheter device that dilates Schlemm’s canal and cuts through trabecular meshwork – was studied in 18 patients (Olander et al., 2026). Baseline mean IOP was 26.1 mmHg. After 12–24 months, IOP had dropped to about 15.5 mmHg (a 9.7–10.6 mmHg reduction)【Olander2026】, and most patients reduced or stopped their drops. In fact, 67% of patients were off glaucoma medications by 24 months【Olander2026】. Adverse events were mostly mild; no eye lost vision or suffered major complications, and only one case of dry eye was thought related to the procedure【Olander2026】. This demonstrates that opening the canal can yield a ~40% pressure reduction, comparable to traditional glaucoma surgery but with a very favorable safety profile. Patient Factors and Choosing a Protocol Eye Color/Pigmentation: SLT and micropulse lasers target pigmented cells in the drainage tissue. Evidence suggests micropulse methods work well even in darkly pigmented eyes: animal data show these pulses trigger enzymes that remodel the trabecular meshwork without excessive heat【Abramowitz2018】. In practice, no major differences in efficacy by eye color have been reported. All these laser options are intended for open-angle glaucoma; they are ineffective in eyes with closed or very narrow angles. Angle Status: All the laser treatments above require at least a partially open drainage angle. If your angle is closed, the first step is typically a laser peripheral iridotomy or a cataract operation to open the angle. The canal-based surgeries are usually done in open-angle eyes too (often at the time of cataract surgery). Prior Therapy: Timing matters. The direct SLT study found bigger pressure drops in eyes that had never used drops before【Goldberg2026】. For example, medication-naïve eyes had a 20.2% IOP reduction after 2 months of DSLT, versus 14.2% in eyes already on drops【Goldberg2026】. This suggests earlier use of laser (before maximal medications) may give a better percentage drop. In general, laser trabeculoplasty (any type) can be repeated if needed. In the micropulse cyclo series, about one-third of eyes needed a second session to reach target (yielding ~75% success by one year)【Toptan2026】. Expected Results: Based on these studies, patients can expect a moderate IOP drop on average. SLT or micropulse trabeculoplasty (360° treatment) typically reduces pressure by 15–25%, helping ~30–67% of eyes reach their goal with one treatment【Goldberg2026】【Abramowitz2018】. Micropulse cyclodestruction often gives ~40–50% drops and usually requires scheduling 1–2 sessions【Toptan2026】. Canal procedures (like OMNI) can cut IOP by ~40% as well【Olander2026】. However, individual response varies widely. If you have high baseline pressure or aggressive glaucoma, a bigger intervention (multiple sessions, cyclo, or combined surgery) may be needed versus a mild case where single-session SLT suffices. Safety Profile: All these lasers are generally safe when used correctly. In the new studies, serious complications were rare. SLT (even direct SLT) mainly causes brief redness or tiny bleeds, and pressure spikes were under 2%【Goldberg2026】. Micropulse lasers spare tissue and caused minimal inflammation – in one report almost no eyes had permanent loss of vision or severe hypotony【Toptan2026】. Canal surgeries like OMNI had a few mild events (dry eye, transient inflammation) but no vision loss【Olander2026】. Overall, these methods are much less invasive than traditional surgery (trabeculectomy) and typically do not carry high risks of blindness or severe complications. Conclusion July 2026 studies show that innovations in glaucoma lasers are yielding more options beyond standard SLT. Modified SLT techniques (non-contact devices or micropulse pulses) match SLT’s pressure lowering with the promise of quicker treatment and less discomfort【Goldberg2026】【Abramowitz2018】. Micropulse cyclophotocoagulation is proving to be a powerful tool for hard-to-control glaucoma, cutting pressure by nearly half in many eyes with minimal side effects【Toptan2026】. And canal-targeted procedures (both laser and micro-surgical) are delivering large IOP drops (~10 mmHg Support the show

    12 min
  6. Corneal Biomechanics as a Risk Modifier: Last-Month Evidence

    4d ago

    Corneal Biomechanics as a Risk Modifier: Last-Month Evidence

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/corneal-biomechanics-as-a-risk-modifier-last-month-evidence Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Understanding Corneal Biomechanics and Glaucoma Risk Glaucoma is an eye disease where damage to the optic nerve leads to vision loss. The main known risk factor has long been high intraocular pressure (IOP). However, newer research shows the biomechanical properties of the cornea – essentially how “springy” or deformable the cornea is – also influence glaucoma risk. Two key measures are corneal hysteresis (CH) and dynamic corneal response (DCR) parameters. CH measures how well the cornea absorbs and dissipates energy (think of it as corneal “shock absorption”). DCR parameters come from devices like the Corvis ST, which use a quick air puff and high–speed camera to record corneal deformation. These measures are now easier to get in the clinic thanks to instruments such as the Ocular Response Analyzer (ORA) and Corvis ST () (). Recent evidence suggests both CH and DCR can help predict glaucoma development and progression beyond IOP and corneal thickness (CCT). Measuring Corneal Hysteresis and Corneal Response The ORA (introduced in 2005) uses an air puff and infrared light to estimate CH (). It reports two values: CH and a related Corneal Resistance Factor (CRF). The newer Corvis ST system uses a high-speed Scheimpflug camera (over 4,300 frames/sec) to visualize the actual corneal movement during an air puff (). It yields many dynamic response metrics (like deformation amplitude, inverse radius, stiffness) beyond CH () (). Importantly, each device produces different parameters, and they are not interchangeable. For example, one study found that the Corvis ST’s “biomechanically corrected” IOP (bIOP) did not match the ORA’s cornea-compensated IOP (IOPcc) – the two methods showed weak agreement and should not be used interchangeably (). In practical terms, CH (from ORA) and DCR metrics (from Corvis) reflect related but distinct corneal properties () (). Clinicians are beginning to incorporate these tests: one expert review even recommends checking corneal biomechanics at baseline in all glaucoma patients and suspects (). This means measuring CH (and possibly Corvis metrics) as part of the initial exam. In summary, corneal biomechanics can now be measured clinically, and experts suggest doing so in glaucoma care () (). ... Continue reading at https://visualfieldtest.com/en/corneal-biomechanics-as-a-risk-modifier-last-month-evidence Support the show

    11 min
  7. Diurnal and Nocturnal Behavior of Episcleral Venous Pressure

    5d ago

    Diurnal and Nocturnal Behavior of Episcleral Venous Pressure

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/diurnal-and-nocturnal-behavior-of-episcleral-venous-pressure Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Daily Rhythms of Eye Pressure and Venous Pressure Our eyes have a natural 24-hour cycle of pressure changes. Both intraocular pressure (IOP) (the pressure of fluid inside the eye) and episcleral venous pressure (EVP) (the downstream pressure in the veins on the surface of the eye) tend to be highest in the early morning and lower by evening () (). In one recent study of healthy adults, the mean IOP and EVP were both highest at 8 AM and fell by late afternoon (). In other words, like a clock, IOP and EVP peak in the morning and wane later in the day () (). However, night‐time patterns are influenced by sleep posture. When we lie down on our back, blood settles differently, so both IOP and EVP rise. For example, one study found that as soon as a person lies down, EVP jumps by about 3–4 mmHg and stays high while supine (). This contributes to known findings that eye pressure measured at night (when a person is usually lying flat) tends to be higher than daytime sitting measurements () (). In one carefully controlled sleep-lab experiment, volunteers showed higher mean IOP at night partly due to increased EVP and fluid shifting when lying down (). Thus nighttime IOP often exceeds daytime levels because of the supine position and higher venous pressure. In general, IOP and EVP move together across the day. When one study compared them round‐the‐clock, changes in EVP closely paralleled changes in IOP () (). In both healthy people and those on blood-pressure medicines, higher EVP in the morning accompanied higher IOP, and both fell through the afternoon () (). This synchronization means factors that push IOP up (like lying down) also raise EVP, since EVP partly “holds up” IOP from falling below it () (). In short, EVP and IOP share daily rhythms with morning peaks and day/evening troughs () (), but staying flat in bed at night produces higher values for both. How Lifestyle and Body Factors Can Change EVP Several everyday factors affect eye pressures. Staying well hydrated, dietary choices, and nervous system activity all play a role: Hydration (Water Intake): Drinking lots of fluid quickly can raise eye pressure. In one classic study, healthy people who drank a liter of water saw their IOP jump by about 4.4 mmHg for over two hours (). This happens because extra fluid increases the blood and ocular fluid volume. By analogy, EVP likely rises a bit with high fluid intake, although direct EVP data is limited. In clinical practice, patients are sometimes advised to avoid gulping large volumes of water right before IOP checks. Salt Intake: Eating very salty food leads the body to retain water, raising blood volume and pressure. Recent research in a large population found that people with higher dietary salt (measured by urine sodium) had slightly higher IOP and more glaucoma (). The highest-salt group had IOP about 0.45 mmHg above the lowest-salt group. Scientists suggest this may be due to more fluid volume and higher episcleral venous pressure pushing fluid back into the eye (). In other words, excess salt can subtly elevate EVP (and thus IOP) and may increase glaucoma risk () (). Caffeine (Coffee): Caffeine is a mild stimulant that briefly raises IOP. In the same classic study, drinking caffeine led to about a 4.0 mmHg rise in IOP lasting around 95 minutes (). The mechanism likely involves caffeine’s vascular effects. We have less direct data on EVP after caffeine, but by raising overall ocular pressure, it may also raise EVP slightly. For patients sensitive to eye pressure changes, avoiding strong coffee or energy drinks before an eye exam can help avoid an artificial spike. Alcohol: Alcohol has the opposite effect. The 1986 study showed that drinking alcohol caused IOP to drop by up to 3.7 mmHg, with values returning to normal within about an hour (). Alcohol is a vasodilator (it relaxes blood vessels), which may lower both blood and venous pressures, including the episcleral veins. So moderate alcohol can transiently lower EVP and IOP, but this is not considered a therapy (and excessive drinking has many risks). For measurement, it implies having an alcoholic drink just before a pressure check might temporarily make one’s IOP/EVP look lower than usual. Autonomic (Stress and Nerves): The autonomic nervous system (our “fight-or-flight” vs “rest-and-digest” system) can adjust vessel tone throughout the body, including the episcleral vessels. Studies note that changes in autonomic activity can change EVP (). For example, being stressed or anxious (activating the sympathetic system) can constrict some eye vessels, whereas relaxation (parasympathetic) may dilate them. One observation: vigorous exercise caused an immediate drop in IOP of about 4.3 mmHg (). This might be partly due to changes in blood flow and venous tone. In practice, rapid heart rate or adrenaline can slightly alter EVP as well. It is wise to sit quietly before measuring eye pressure, to let things settle. Body Posture: Moving from sitting to lying increases EVP. Multiple studies show that IOP measured lying down is consistently ~2–4 mmHg higher than when sitting (). This is largely due to higher EVP when supine. Thus doctors usually check IOP in a seated position for consistency. But patients should remember: when they lie down (for sleep or rest), their eye pressures rise. Eyelid Closure: As it turns out, simply closing the eyelid (such as when dozing) does not significantly change EVP or IOP (). One study found no effect from keeping one eye closed overnight. So it’s the posture (supine) rather than blinking or shut eyelid that drives pressure changes at night. In summary, factors that boost blood/eye fluid (like too much salt or water, caffeine, lying flat) tend to raise EVP and IOP, while vasodilators or activity (alcohol, exercise) tend to lower them () (). Patients may be advised to minimize heavy salt, caffeine, and alcohol around the time of pressure checks. Implications for Monitoring and Treatment These rhythms and triggers have real-world impacts on glaucoma care. Because IOP (and EVP) peak in the morning, relying on a single afternoon office measurement can miss dangerous spikes () (). A patient whose IOP is “normal” at 2 PM might actually have had a higher pressure earlier that day. Therefore, doctors sometimes repeat IOP checks at different times, or even use extended monitoring. For example, one noninvasive device (the Triggerfish® contact lens sensor) records 24-hour ocular pressure patterns continuously, including while sleeping (). Studies show this lens can safely capture the ups and downs of IOP (and inferred EVP changes) around the clock (). If available, such monitoring can reveal night-time peaks or large swings that single visits miss. Without that technology, home tonometry (self-measuring IOP) or evening clinic visit can help find the highest pressures. Medication timing can also consider these patterns. Many glaucoma eye drops work over 24 hours, but some effects vary. For instance, carbonic anhydrase inhibitors and beta-blockers reduce fluid production, so giving them before the morning rush might blunt the rise. Prostaglandin analogs increase outflow and usually act over a full day, so they are often given at bedtime to cover the early morning period. In any case, discussing timing with one’s doctor is wise. A typical strategy is to try to have the maximum drug effect coincide with the known IOP peak (often morning) () (). (Some doctors note, for example, that beta-blockers like timolol may work best if dosed in the morning when sympathetic tone is higher.) There is no single rule for all patients, but understanding that EVP and IOP ebb and flow suggests chronotherapy (timed dosing) could optimize control. Practically speaking, patients should follow these tips: Record Multiple Readings: If possible, get IOP measurements at different times (morning and afternoon, or during a home period) to catch peaks. Consistent Posture: Always measure IOP sitting upright, both at home or clinic. Note that lying down (even for sleep) raises the pressure. Report Drinks or Meds: Let the doctor know about large water intake, caffeine, salt meals, or new medications (like oral decongestants or stimulants) around measurement time. Tailor Eye Drops: Ask the doctor if any medication timing should adjust for your daily schedule (e.g. take certain drops at night vs morning). By aligning treatment and monitoring with the eye’s daily cycle, one can better manage glaucoma risk. For example, if a patient’s pressure is highest upon waking, an evening dose of medication might be most effective, whereas a midday peak might call for a morning dose. There is ongoing research on “ocular chronotherapy,” but the key idea is clear: when and how often we measure and treat should reflect the clock-like behavior of eye pressure. Recommendations for Future Research Protocols To better understand EVP’s 24-hour behavior, future studies should use standardized, controlled protocols. Here are some suggestions: Controlled Environment: Use a sleep-lab or clinical research setting where lighting, temperature, and noise are kept constant. Keep subjects on a strict sleep-wake schedule (e.g. lights on at 7 AM, off at 11 Support the show

    13 min
  8. The Optic Nerve Head Perfusion Equation: Venous Pressure, IOP, and Susceptibility to Damage

    Jul 1

    The Optic Nerve Head Perfusion Equation: Venous Pressure, IOP, and Susceptibility to Damage

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-optic-nerve-head-perfusion-equation-venous-pressure-iop-and-susceptibility-to-damage Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: The Optic Nerve Head Perfusion “Equation”: Balancing Arterial and Venous Pressures Glaucoma (optic nerve damage) has long been linked to high intraocular pressure (IOP), but doctors now recognize that blood flow through the eye is just as important to optic nerve health. In the eye, blood enters through arteries carrying a high pressure from the heart, and must exit through veins carrying lower pressure. The perfusion pressure that drives blood through the optic nerve head (ONH, where the nerve fibers exit the eye) depends on the difference between these pressures – but with a twist. Unusually, the eyeball’s pressure (IOP) physically squeezes the veins leaving the eye (the vortex and episcleral veins) so that these veins must have pressures just above IOP to stay open (). In other words, ocular veins behave like a “Starling resistor”: their outflow pressure is kept near IOP to prevent collapse. This means eye perfusion pressure is often approximated as arterial pressure minus IOP (). In practice, doctors often estimate ocular perfusion pressure (OPP) by subtracting IOP from mean arterial pressure (roughly ⅔ of blood pressure) () (). However, this is only an approximation. Actual venous pressure can deviate from IOP, especially at low IOPs (), which makes true perfusion pressure lower than the formula predicts. In one eye model, researchers found choroidal venous pressure stayed higher than IOP, so real perfusion might be overestimated by the simple formula (). In addition to IOP acting from inside the eye, the optic nerve head lamina cribrosa (the sieve-like tissue at the back of the eye) is also pressed on by the pressure in the cerebrospinal fluid (CSF) around the optic nerve. Normally CSF pressure (essentially intracranial pressure) is somewhat lower than IOP, so the lamina sees a net gradient pushing it backwards. This translaminar pressure difference (IOP minus CSF pressure) causes posterior bowing of the lamina; when it is large, nerve fibers and blood vessels in the lamina can be strained () (). For example, if IOP is 20 mmHg and CSF pressure is 10 mmHg, the lamina experiences about a 10 mmHg difference. Since the lamina is only a few hundred micrometers thick, that works out to roughly 1 mmHg of gradient per 100 µm of tissue () – one of the steepest pressure gradients in the body. Animal and human studies suggest that this translaminar gradient itself can damage the optic nerve. In fact, modern research shows that a low CSF pressure (leading to a high IOP–CSF difference) can be as damaging to the optic nerve head as a high IOP . In normal-pressure glaucoma patients (IOP 21 mmHg), low blood pressure or especially low CSF pressure can excessively increase this gradient, starving the lamina of blood flow () (). How Arteries and Veins Drive ONH Perfusion As in any tissue, arterial blood pressure pushes blood into the eye’s circulation, and resistance in the tiny vessels reduces pressure by the time blood reaches the veins. Normally this sets up a downward pressure gradient from arteries to veins. But in the eye the external pressure of IOP compresses the outflow veins, forcing the vein pressure to stay just above IOP (). In practice this means blood must overcome the sum of IOP and any venous pressure to reach the tissues of the ONH. In simple terms, ocular perfusion pressure is often taken as arterial pressure minus IOP (), assuming venous pressure ≈ IOP. This approximation highlights two key factors for flow: arterial pressure (linked to heart blood pressure) and IOP. If blood pressure drops (for example at night) or IOP spikes, perfusion can fall. Indeed, wide swings in IOP or blood pressure are risk factors for glaucoma damage. Recent work confirms that large fluctuations in calculated OPP (blood pressure minus IOP) are linked to progression of normal-tension glaucoma (). For instance, one trial found that although both latanoprost and bimatoprost lowered IOP equally, only latanoprost significantly raised the eye’s calculated perfusion pressure (likely through modest effects on blood flow) (). Importantly, the above formula neglects direct venous pressure terms. In reality, if venous pressure is elevated (for example by raised intracranial pressure, or conditions like heart failure or obstructive breathing that raise thoracic pressures), perfusion pressure is reduced. Research in animal eyes shows that at low IOPs venous pressure can actually exceed IOP, causing actual perfusion pressure (arterial minus venous) to be less than the simple MAP–IOP estimate (). In glaucoma patients, higher episcleral venous pressure (EVP) has been observed with some treatments, blunting pressure reduction (). In one animal model, experimentally raising venous pressure dramatically lowered ONH perfusion. Altogether, narrowing or congestion of the ocular veins lowers the overall pressure gradient that drives blood through the optic nerve, making the nerve tissue more susceptible to damage even if IOP is not very high. Imaging and Blood-Flow Studies in Glaucoma Modern imaging and blood-flow measurements confirm that glaucoma eyes often suffer from poor optic nerve perfusion. Optical coherence tomography angiography (OCTA) shows that glaucoma is associated with loss of capillaries: vessel density in the retina, around the nerve, and in the peripapillary choroid is significantly lower in glaucoma patients (). These microvascular defects correlate closely with nerve fiber loss and visual field defects, suggesting a link between poor blood supply and nerve damage (). In one OCTA study, the overall optic disc “flow index” (a measure of blood flow) was about 25% lower in glaucoma eyes than in normals, even after accounting for scan variability (). Hemodynamic imaging adds to this picture. Color Doppler ultrasound studies show that blood velocities in the eye’s feeding arteries (ophthalmic, central retinal, and short posterior ciliary arteries) are lower in both high-tension and normal-tension glaucoma than in healthy eyes (). Laser-based flowmetry assays similarly record reduced blood flow on the surface of the optic nerve head in glaucoma. For example, laser Doppler velocimetry finds less blood in the small capillaries nourishing the nerve fiber layer of glaucoma eyes (). Scanning laser flowmetry in the nerve head cup and rim also consistently shows lower microvascular perfusion in glaucoma patients than in healthy or ocular-hypertension subjects (). Notably, these reductions in flow correlate with the extent of nerve damage: more severe glaucoma tends to coincide with greater loss of ONH perfusion (). Other techniques have similar findings. Laser speckle flowgraphy (LSFG) studies indicate that even at the earliest stages of glaucoma the optic nerve head blood flow can initially rise (possibly from loss of autoregulation) and then steadily declines as damage progresses (). By the time a large fraction of the nerve fiber layer is lost, ONH blood flow can be 25% below baseline (). Long-term studies also suggest that eyes with poorer baseline perfusion – for example due to higher vascular resistance – are more likely to go on to lose visual field faster. For instance, in a 3-year study of treated glaucoma patients, those who progressed showed higher resistivity (lower flow) in the ophthalmic and ciliary arteries at baseline (). Together, these imaging and blood-flow data show a clear pattern: glaucoma optic nerves often have less blood flow and perfusion than normal. While this is partly a consequence of IOP-related compression (a narrowed pressure gradient), it also implies that any additional factor that reduces flow – such as venous congestion or low arterial pressure – can compound the problem. Therapeutic Approaches: Beyond Just Lowering IOP Because glaucoma damage can happen even at normal IOP, researchers emphasize treatments that also protect or improve optic nerve blood flow. Lowering IOP remains first-line, but supplemental strategies target the vascular side. Some glaucoma drugs have beneficial blood-flow effects. For example, the alpha-2 agonist brimonidine not only lowers IOP, it also improves retinal and ONH circulation. Although brimonidine constricts some vessels on the eye’s surface, it paradoxically dilates retinal arterioles and increases overall ocular blood flow (). Clinically, in one trial of normal-tension glaucoma, patients on brimonidine lost visual field more slowly than those on timolol even though their IOPs were the same (), suggesting the improved perfusion provided some protection. Prostaglandin analogues (first-line IOP drugs) may also affect perfusion. Laboratory studies found that latanoprost enhanced optic nerve blood circulation (in animals and humans) independently of its IOP effect (). In a clinical trial comparing latanoprost with bimatoprost, both drugs lowered IOP equally, but only latanoprost increased calculated ocular perfusion pressure (). It appears that some medications can also change the downstream venous pressure – for example, topical prostaglandins were found to raise episcleral venous pressure in animals (), partially offsetting their benefit. New approaches are looking t Support the show

    13 min
See All (210)

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information